Jennison Associates
CNCE

Jennison Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Jennison Associates’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-337,193
Closed -$6.33M – 746
2015
Q3 		$6.33M Buy
337,193
+2,507
+0.7% +$42.6K 0.01% 531
2015
Q2 		$4.98M Sell
334,686
-145,536
-30% -$2.22M ﹤0.01% 539
2015
Q1 		$7.27M Buy
+480,222
New +$6.7M 0.01% 504

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Jennison Associates's CNCE Position: Q4 2015 in Review

Jennison Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2015, closing a stake of 337,193 shares — an estimated $6.33M sold.

Jennison Associates first reported a position in CNCE in Q1 2015 and held it in 3 quarters. The position peaked at $7.27M in Q1 2015. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2015.

  • Jennison Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 337,193 Concert Pharmaceuticals, Inc. shares in Q4 2015, an estimated $6.33M.
  • Jennison Associates first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • Jennison Associates's Concert Pharmaceuticals, Inc. position peaked at $7.27M in Q1 2015.
  • 93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.